1-(Tert-Butoxycarbonyl)Pyrrolidine-3-Carboxylic Acid Methyl Ester

How does the N-Boc methyl ester scaffold tolerate Grignard addition without racemization?

Conversion of the ester to a Weinreb amide prior to organometallic addition is the preferred route in cGMP intermediate manufacture, avoiding ketone formation and preserving stereochemical integrity at C3. In a jacketed 20 L glass-lined reactor under nitrogen, 1.0 eq of 1-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid methyl ester is treated with N,O-dimethylhydroxylamine hydrochloride (1.2 eq) and isopropylmagnesium chloride (2.4 eq) in THF at −15 °C. The reaction mass is aged for 90 min, then quenched into aqueous NH₄Cl (15% w/w) while maintaining the internal temperature below 0 °C. The Weinreb amide is extracted with ethyl acetate, dried over Na₂SO₄, and concentrated on a rotary evaporator fitted with a dry-ice condenser.

Isolated yield reaches 91% with HPLC purity 99.2 area% (detection at 210 nm, C18 column, acetonitrile/water gradient). Subsequent addition of aryl Grignard reagents at −20 °C delivers the corresponding ketone, a key intermediate for chemokine receptor antagonists. Process analytical technology (ReactIR) monitors the disappearance of the amide carbonyl stretch at 1650 cm⁻¹. The batch record specifies compliance with ICH Q7 Section 12.5 for process validation. Residual solvents are controlled per USP <467> (THF ≤ 720 ppm, isopropanol ≤ 5000 ppm). The terminal API derived from this ketone is crystallized to ≥ 99.5% purity. A critical operational boundary: the Boc group undergoes partial cleavage if the Grignard quench pH drops below 6.0; therefore, the aqueous phase is buffered with 10% K₂HPO₄. Limitation: large-scale Grignard reactions require rigorous moisture exclusion (KF < 50 µg/g) to avoid diarylketone side-product formation, and the Weinreb amide itself must be stored at −20 °C to prevent N–O bond scission.

Backbone conformational constraint in Leu-enkephalin analogs was achieved via ester saponification to the free acid, followed by on-resin coupling using PyBOP in DMF with 0.4 M N-methylmorpholine. The methyl ester is treated with LiOH·H₂O (1.05 eq) in THF/H₂O (3:1 v/v) at 0 °C for 2 h. After acidification with citric acid and extraction, the N-Boc-3-carboxypyrrolidine is isolated as a white lyophilisate. This β-amino acid surrogate is then coupled to a resin-bound hexapeptide on ChemMatrix PEG resin using PyBOP (3.0 eq) and NMM (6.0 eq) with a 45 min double-coupling cycle. Coupling efficiency is monitored by the Kaiser test; a third coupling is triggered if residual free amine exceeds 2 µmol/g. The linear protected peptide is cleaved with TFA/TIS/H₂O (95:2.5:2.5) and cyclised in DMF at 1 mM concentration using DEPBT as the cyclisation reagent.

Chiral HPLC (Chiralpak AD-H, 250 × 4.6 mm, hexane/ethanol 85:15, 0.8 mL/min) must confirm enantiomeric excess ≥ 99.0% for the N-Boc acid intermediate, because epimerisation at C3 occurs if the saponification temperature exceeds 8 °C. The final cyclic peptide is lyophilised and released per FDA 21 CFR 210.1. A documented incompatibility: the Boc group is labile in the presence of TFA vapor; all handling of the acid intermediate is conducted in HEPA-filtered isolators with relative humidity < 30%. At production scale, 1 kg batches of the N-Boc acid are prepared and immediately converted to the Fmoc derivative to circumvent stability issues.

The starting material for the described transformations is typically supplied with the following release criteria, established via industrial batch analysis and aligned with pharmacopoeial general chapters.

Pyrrolidine-3-carboxylic Acid Methyl Ester as a Scaffold for Hydrogen-Bonding Thiourea Catalysts

Removal of the Boc group with HCl gas in dioxane (4 M, 3 vol) at 20 °C liberates the hydrochloride salt. Neutralisation with saturated NaHCO₃ and extraction with DCM provides the free amine, which is immediately treated with 3,5-bis(trifluoromethyl)phenyl isothiocyanate (1.05 eq) in anhydrous DCM. The resulting thiourea-equipped pyrrolidine-3-carboxylic acid methyl ester is purified by flash chromatography (silica, hexane/EtOAc 7:3) to give the bifunctional organocatalyst as a white solid. The entire sequence is executed in a single train of Hastelloy reactors under Schlenk conditions, with solvent moisture content kept below 10 ppm as verified by Karl Fischer coulometry.

The catalyst is evaluated in the asymmetric conjugate addition of nitromethane (10 eq) to trans-β-nitrostyrene at 5 mol% loading in toluene at 25 °C. Enantiomeric excess reaches 87% (determined by chiral SFC, Chiralpak IC-3, 4.6 × 100 mm, CO₂/MeOH 95:5, 3 mL/min). Regulatory filings for catalyst residues in the final API follow the EMEA guideline on metal catalysts; the thiourea adduct itself must be purged to < 10 ppm using silica gel filtration and activated carbon treatment. The catalyst is not a terminal product but an in-house synthesis tool. A known operational pitfall: the free pyrrolidine base is hygroscopic and absorbs atmospheric CO₂, forming an unreactive carbamate salt. Storage and transfer must be performed under argon, and the isothiocyanate coupling initiated within 30 min of neutralisation to limit degradation.

Construction of neonicotinoid analog libraries begins with reduction of the methyl ester to the primary alcohol. In a 100 L stainless-steel reactor, NaBH₄ (1.5 eq) and LiCl (2.0 eq) are suspended in THF/ethanol (4:1), and the N-Boc ester is added portionwise at 20–25 °C. The batch is aged for 6 h, quenched with saturated NH₄Cl, and the alcohol isolated by ethyl acetate extraction. The alcohol is then mesylated (1.1 eq MsCl, 1.2 eq Et₃N, DCM, 0 °C) and displaced with sodium azide (1.5 eq) in DMF at 80 °C to yield the 3-azidomethyl-pyrrolidine intermediate. Copper-catalysed azide-alkyne cycloaddition with substituted propargyl amines in tert-butanol/water at 25 °C (CuSO₄·5H₂O 0.05 eq, sodium ascorbate 0.2 eq) generates a 200-member library of triazole adducts.

Purity of the azide intermediate is limited to ≥ 95 area% for library synthesis; flash purification on a 20 cm Biotage column with heptane/ethyl acetate gradients is employed. Insecticidal activity is measured against Aphis gossypii (LC₅₀ values in foliage-dip assays), but no GLP safety studies are conducted at the intermediate stage. Export compliance requires a Safety Data Sheet conforming to GHS Revision 8, with hazard codes H302, H315, H319. Strict prohibition: the azide intermediate must not come into contact with chlorinated solvents during heating above 60 °C owing to the risk of explosive chloroazide formation. All waste streams containing residual azide are quenched with sodium nitrite in acidic solution before disposal.

If the methyl ester is transesterified with HEMA without Boc cleavage

Functional monomers for acid-labile polymer networks are prepared by titanium(IV)-catalysed transesterification of the methyl ester with 2-hydroxyethyl methacrylate (HEMA). A mixture of the N-Boc pyrrolidine ester (1.0 eq), HEMA (3.0 eq), and titanium(IV) isopropoxide (0.5 mol%) is heated under reduced pressure (100 mbar) at 110 °C, with methanol distilled off to drive the equilibrium. The monomer is then purified by flash column chromatography (silica, hexane/EtOAc 4:1) to remove excess HEMA. Subsequent free-radical copolymerisation with methyl methacrylate (MMA) is initiated by AIBN (1 mol%) at 70 °C in toluene, yielding random copolymers with 15–30 mol% pyrrolidine-co-HEMA content. These copolymers exhibit pH-dependent swelling due to the Boc-protected amine; deprotection in the solid state with TFA vapour reveals amino groups that protonate at endosomal pH 5.5.

The final product is evaluated as a drug-delivery nanoparticle matrix. Compliance with ISO 10993-5 for in vitro cytotoxicity is required for biomedical use. Residual monomer content is determined by GC-MS and must be ≤ 500 ppm for MMA and ≤ 200 ppm for the methacrylate monomer. A crucial processing limitation: transesterification temperatures above 120 °C cause thermal elimination of the Boc group and premature crosslinking; therefore, a short-path distillation apparatus with precise temperature control is installed. The maximum batch size trialed to date is 500 g, with yields reaching 78%. Monomer shelf life at −20 °C is 6 months when 50 ppm 4-methoxyphenol is added as inhibitor.

Positron emission tomography (PET) tracer development utilises the 3-azidomethyl-pyrrolidine intermediate described above for ¹⁸F incorporation via strain-promoted or copper-catalysed click chemistry. The Boc-protected azide is reacted with a ¹⁸F-labelled alkyne-bearing prosthetic group in a microfluidic flow reactor at 80 µL/min flow rate, achieving 65–75% radiochemical conversion (decay-corrected) within 12 min. Boc deprotection is performed post-click using TFA at 60 °C for 5 min, followed by HPLC purification on a semi-preparative C18 column (Phenomenex Luna, 10 × 250 mm, 4 mL/min) to provide the ¹⁸F-labelled compound with radiochemical purity ≥ 99% and molar activity ≥ 50 GBq/µmol at end of synthesis.

The entire process is executed inside a lead-shielded hot cell compliant with GMP for PET radiopharmaceuticals per USP <823>. The precursor (Boc-protected azide) is released for synthesis only after passing a bioburden test (< 10 CFU/mL) and a bacterial endotoxin test (< 5 EU/mL). Due to the 109.8 min half-life of ¹⁸F, the entire synthesis, purification, and quality control must be completed within 55 min. A documented incompatibility: trace acetonitrile from HPLC purification can inhibit the deprotection step if not evaporated completely; therefore, a rotary evaporation step at 40 °C under nitrogen flow is inserted before TFA treatment. Storage of the unlabelled precursor is at −20 °C under argon in single-use vials to prevent moisture uptake and azide degradation.